Correction: Challenges and Solutions in Developing New Medications for Schizophrenia

See related article by Potkin, et al.

Correction

In the Academic Highlights “Challenges and Solutions in Developing New Medications for Schizophrenia” (J Clin Psychiatry 2010;71[10]:1391-1399), all Ki values in the section “New Antipsychotics and Investigational Agents” should be pKi values. Table 1 should be corrected as follows: the pKi of iloperidone is 0.3 nM for α1 and the pKi of asenapine is 1.3 nM for D2, 0.07 nM for 5-HT2A, 2.7 nM for 5-HT1A, 0.11 nM for 5-HT7, 1.2 nM for both α1 and α2, 1.0 nM for H1, and > 5,000 nM for M1. Additionally, in the “Muscarinic (M1) Effects” section on page 1396, asenapine should be deleted from the list of agents with potent affinity for the M1 receptor. In the “Newer Antipsychotics: Asenapine” section, the third sentence should read: “It is generally well tolerated, with somnolence the most common side effect due to its high affinity for H1 receptors; however, despite its H1 affinity, little weight gain has been observed (average of only 2 lb in year-long studies).”

The online table and text have been corrected.